12 years or older:
Cream, gel, ointment: Apply a thin film to the affected area once or twice a day.
Foam, lotion: Apply twice a day (once in the morning and once at night)
-Treatment should be limited to two weeks.
-Use should be limited to 45 g per week.
-This topical drug should not be used with occlusive dressings, unless directed by a healthcare provider.
-If an infection develops, appropriate antimicrobial therapy should be initiated.
Use: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
This information should not be used to decide whether or not to take betamethasone injection or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to betamethasone injection. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.
In an international, multi-center, double-blind, vehicle- and active-controlled, parallel-group study, 1,603 patients with mild to very severe psoriasis vulgaris on trunk and limbs were treated once daily for 4 weeks. Patients were randomized to one of four treatment arms: Taclonex® (calcipotriene and betamethasone dipropionate) Ointment, calcipotriene hydrate 50 mcg/g in the same vehicle, betamethasone dipropionate mg/g in the same vehicle, and vehicle alone. The mean age of the patients was years and % were male. Most patients had disease of moderate severity at baseline.